Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Accured ExpensesChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to -$151309.0.

  • Bioadaptives' Net Cash Flow fell 44657.79% to -$151309.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$266620.0, marking a year-over-year decrease of 9006.95%. This contributed to the annual value of $76694.0 for FY2024, which is 11682.73% up from last year.
  • According to the latest figures from Q3 2025, Bioadaptives' Net Cash Flow is -$151309.0, which was down 44657.79% from -$110982.0 recorded in Q2 2025.
  • Over the past 5 years, Bioadaptives' Net Cash Flow peaked at $111951.0 during Q3 2023, and registered a low of -$151309.0 during Q3 2025.
  • Its 5-year average for Net Cash Flow is -$13653.2, with a median of -$11339.0 in 2022.
  • Its Net Cash Flow has fluctuated over the past 5 years, first surged by 305768.07% in 2021, then crashed by 165450.37% in 2023.
  • Quarter analysis of 5 years shows Bioadaptives' Net Cash Flow stood at $16597.0 in 2021, then plummeted by 64.61% to $5873.0 in 2022, then plummeted by 1654.5% to -$91296.0 in 2023, then surged by 202.5% to $93577.0 in 2024, then crashed by 261.69% to -$151309.0 in 2025.
  • Its last three reported values are -$151309.0 in Q3 2025, -$110982.0 for Q2 2025, and -$97906.0 during Q1 2025.